VEGFA and colorectal carcinoma: Similarly, anti‐angiogenic drug bevacizumab, which targets VEGF, is also approved for clinical use in advanced stage CRC and could be investigated for TMS3 patients due to the enrichment of the hallmark angiogenesis pathway [30].